ArticleeLife2019
Obesity-linked suppression of membrane-bound
Open access · goldAbstract read
In one paragraph
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
10.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.Journal of hepatology · 2021Pooled it
- Genetic and genomic insights across the steatotic liver disease spectrum.Clinical and molecular hepatology · 2026Review
- Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Genetic and lifestyle determinants of lipid profiles in Japanese young adults: evidence from MBOAT7 rs641738.Lipids in health and disease · 2026Article
- The genetics of obesity: aetiology, prevention and therapy.Nature metabolism · 2026Review
- Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease.International journal of molecular sciences · 2025Review
- Physiological roles of phosphoinositides and inositol phosphates: Implications for metabolic dysfunction-associated steatotic liver disease.Clinical science (London, England : 1979) · 2025Review
- Clinical and Genetic Predictors of Non-Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Hepatic ASPG-mediated lysophosphatidylinositol catabolism impairs insulin signal transduction.The EMBO journal · 2025Article
- Hepatic Inactivation of Carnitine Palmitoyltransferase 1a Lowers ApoB-Containing Lipoproteins in Mice.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment.The Journal of clinical investigation · 2025Review
- Proximity proteomics reveals a mechanism of fatty acid transfer at lipid droplet-mitochondria- endoplasmic reticulum contact sites.Nature communications · 2025Article
- PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on "TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD".Clinical and molecular hepatology · 2025Article
- Lipidomic profiling of mouse brain and human neuron cultures reveals a role forScience translational medicine · 2025Article
- Metabolomics at the cutting edge of risk prediction of MASLD.Cell reports. Medicine · 2024Review
- AS160 is a lipid-responsive regulator of cardiac CaNature communications · 2024Article
- Gut microbes, diet, and genetics as drivers of metabolic liver disease: a narrative review outlining implications for precision medicine.The Journal of nutritional biochemistry · 2024Review
- Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy.World journal of gastrointestinal pathophysiology · 2024Review
- Phospholipid Acyltransferases: Characterization and Involvement of the Enzymes in Metabolic and Cancer Diseases.Cancers · 2024Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 7 institutions in 1 country.
Robert N HelsleyDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.ORCID 0000-0001-5000-3187
Venkateshwari VaradharajanDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Amanda L BrownDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Anthony D GromovskyDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Rebecca C SchugarDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Iyappan RamachandiranDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Kevin FungDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Mohammad Nasser KabbanyDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Rakhee BanerjeeDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Chase K NeumannDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Chelsea FinneyDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Preeti PathakDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Danny OrabiDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Lucas J OsbornDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
William MasseyDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Renliang ZhangDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Anagha KadamDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Brian E SansburyCenter for Experimental Therapeutics & Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
Calvin PanDepartment of Medicine, University of California, Los Angeles, Los Angeles, United States.
Jessica SacksDepartment of Pathobiology, Cleveland Clinic, Cleveland, United States.
Richard G LeeCardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, United States.
Rosanne M CrookeCardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, United States.
Mark J GrahamCardiovascular Group, Antisense Drug Discovery, Ionis Pharmaceuticals, Inc, Carlsbad, United States.
Madeleine E LemieuxBioinfo, Plantagenet, Canada.
Valentin GogoneaDepartment of Chemistry, Cleveland State University, Cleveland, United States.
John P KirwanDepartment of Pathobiology, Cleveland Clinic, Cleveland, United States.
Daniela S AllendeDepartment of Anatomical Pathology, Cleveland Clinic, Cleveland, United States.
Mete CivelekDepartment of Biomedical Engineering, University of Virginia, Charlottesville, United States.
Paul L FoxDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.
Lawrence L RudelDepartment of Pathology, Section on Lipid Sciences, Wake Forest University School of Medicine, Winston-Salem, United States.
Aldons J LusisDepartment of Medicine, University of California, Los Angeles, Los Angeles, United States.
Matthew SpiteCenter for Experimental Therapeutics & Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.
J Mark BrownDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, United States.ORCID 0000-0003-2708-7487
Cleveland Clinic · USIonis Pharmaceuticals (United States) · USBrigham and Women's Hospital · USUniversity of California, Los Angeles · USCleveland State University · USUniversity of Virginia · USWake Forest University · US
Funding
TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3MULTRASTRUCTURE OF THE INTIMA IN EARLY LESION FORMATIONP01HL030568 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FOGELMAN, ALAN M · 1985 to 2019
$55.2MClinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0MVascular Cell function and AtherosclerosisP01HL029582 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI FOX, PAUL L · 1985 to 2019
$32.0MTargeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6MTISSUE CULTURE COREP01HL049373 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SHELNESS, GREGORY S · 1993 to 2012
$23.8MProject Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Thomas M McIntyre · 2016 to 2026
$19.6MProject 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic diseaseP01HL147823 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MICHAEL ANDREW FISCHBACH · 2019 to 2026
$17.0MResolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2011 to 2020
$14.8MNon Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2MNovel Therapies for Alcoholic HepatitisU01AA021893 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCLAIN, CRAIG J., MCCULLOUGH, ARTHUR JOSEPH · 2012 to 2017
$6.0MRole of Inflammation-Resolving Lipid Mediators In Ischemic RevascularizationR01HL106173 · NHLBI · UNIVERSITY OF LOUISVILLE · PI SPITE, MATTHEW R · 2011 to 2023
$5.7MNCATS NIH HHS UL1 TR000439NCI NIH HHS P30 CA043703NCI NIH HHS P50 CA150964NHLBI NIH HHS F32 HL136044NHLBI NIH HHS F32-HL136044NHLBI NIH HHS P01 HL029582NHLBI NIH HHS P01 HL030568NHLBI NIH HHS P01 HL049373NHLBI NIH HHS P01 HL147823NHLBI NIH HHS P01-HL30568NHLBI NIH HHS P01-HL49373NHLBI NIH HHS R00-HL12172NHLBI NIH HHS R01 HL106173NHLBI NIH HHS R01-HL106173NHLBI NIH HHS R01 HL122283NHLBI NIH HHS R01-HL122283NIAAA NIH HHS P50 AA024333NIAAA NIH HHS P50-AA-024333NIAAA NIH HHS U01 AA021893NIAAA NIH HHS U01-AA021893NIAMS NIH HHS R21 AR067477NIDDK NIH HHS R01 DK103637NIDDK NIH HHS R01-DK103637NIDDK NIH HHS R01 DK120679NIDDK NIH HHS R01-DK120679NIDDK NIH HHS U01 DK061732NIDDK NIH HHS U01-DK061732NIGMS NIH HHS P01 GM095467
Abstract
Recent studies have identified a genetic variant rs641738 near two genes encoding membrane bound
Indexed as
AcylationAcyltransferasesAnimalsDisease ProgressionHumansMembrane ProteinsMiceNon-alcoholic Fatty Liver DiseaseObesityAcyltransferasesMBOAT7 protein, humanMembrane Proteinshepatologyhuman biologymedicinemouseNAFLDtriacylglycerol
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.